© 2004 European Society of Cardiology
Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP
a Thoraxcenter, Department of Cardiology, University Hospital Groningen P.O. Box 30.001, Groningen 9700 RB, The Netherlands
b Trial Coordination Center, University Hospital Groningen The Netherlands
c Department of Internal Medicine, Erasmus MC Rotterdam, The Netherlands
* Corresponding author. Tel.: +31-50-3612355; fax: +31-50-3614391. E-mail address: d.j.van.veldhuisen{at}thorax.azg.nl
 |
Abstract |
|---|
Background: Natriuretic peptides are currently used in the diagnosis and follow-up of patients with Chronic Heart Failure (CHF). However, it is unknown whether there are different influences of age on atrial natriuretic peptide (ANP)/N-terminal-ANP (NT-ANP) or B-type natriuretic peptide (BNP)/N-terminal-proBNP (NT-proBNP).
Aims: To compare the influence of age and gender on plasma levels of ANP/NT-ANP and BNP/NT-proBNP in CHF patients.
Methods and results: Natriuretic peptides were measured in 311 CHF patients (68±8 years, 76% males, left ventricular ejection fraction (LVEF) 0.23±0.08). All natriuretic peptides were significantly related to age (p<0.05) on multivariate regression analysis, with partial correlation coefficients of 0.18, 0.29, 0.28 and 0.25 for ANP, NT-ANP, BNP and NT-proBNP, respectively. The relative increase of both BNP/NT-proBNP were more pronounced than of ANP/NT-ANP (p<0.01). Furthermore, the relative increase of BNP with age was markedly larger than of NT-proBNP (p<0.01). Levels of all natriuretic peptides were also significantly related to cardiothoracic ratio, renal function and LVEF.
Conclusion: In patients with CHF, BNP/NT-proBNP were more related to age than ANP/NT-ANP, and BNP was more related to age than NT-proBNP. However, in these CHF patients the influence of age on the levels of all natriuretic peptides was modest, and comparable to several other factors.
Key Words: ANP • BNP • Age • Heart failure
Received November 6, 2003; Revised February 11, 2004; Accepted March 26, 2004
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. C.M. Linssen, S. J.L. Bakker, A. A. Voors, R. T. Gansevoort, H. L. Hillege, P. E. de Jong, D. J. van Veldhuisen, R. O.B. Gans, and D. de Zeeuw N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population Eur. Heart J., October 23, 2009; (2009) ehp420v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Voors, S. von Haehling, S. D. Anker, H. L. Hillege, J. Struck, O. Hartmann, A. Bergmann, I. Squire, D. J. van Veldhuisen, K. Dickstein, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study Eur. Heart J., May 2, 2009; 30(10): 1187 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, Y. Zhou, L. Meng, X. Lu, N. Ou, and X. Li Inflammatory Mediators in Chinese Patients With Congestive Heart Failure J. Clin. Pharmacol., May 1, 2009; 49(5): 591 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Frankenstein, A L Clark, K Goode, L Ingle, A Remppis, D Schellberg, F Grabs, M Nelles, J G F Cleland, H A Katus, et al. The prognostic value of individual NT-proBNP values in chronic heart failure does not change with advancing age Heart, May 1, 2009; 95(10): 825 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Masia, J. Papassotiriou, N. G. Morgenthaler, I. Hernandez, C. Shum, and F. Gutierrez Midregional Pro-A-Type Natriuretic Peptide and Carboxy-Terminal Provasopressin May Predict Prognosis in Community-Acquired Pneumonia Clin. Chem., December 1, 2007; 53(12): 2193 - 2201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hogenhuis, A. A. Voors, T. Jaarsma, A. W. Hoes, H. L. Hillege, J. A. Kragten, and D. J. van Veldhuisen Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure Eur J Heart Fail, August 1, 2007; 9(8): 787 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Masson, R. Latini, I. S. Anand, T. Vago, L. Angelici, S. Barlera, E. D. Missov, A. Clerico, G. Tognoni, J. N. Cohn, et al. Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data Clin. Chem., August 1, 2006; 52(8): 1528 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. O. Neverdal, C. W. Knudsen, T. Husebye, O. A. Vengen, J. Pepper, M. Lie, and T. Tonnessen The effect of aortic valve replacement on plasma B-type natriuretic peptide in patients with severe aortic stenosis -- one year follow-up Eur J Heart Fail, May 1, 2006; 8(3): 257 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Jaarsma Inter-professional team approach to patients with heart failure Heart, June 1, 2005; 91(6): 832 - 838. [Full Text] [PDF]
|
|